Vieweg, W Victor R <br/><br/>
Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?  [electronic resource] 

 -  The American journal of medicine  Sep 2012 
 - 859-68 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Review 
<br/><br/><label>ISSN: </label>1555-7162 
<br/><br/><label>Standard No.: </label>10.1016/j.amjmed.2011.12.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antidepressive Agents, Second-Generation--administration & dosage<br/>Citalopram--administration & dosage<br/>Death, Sudden, Cardiac--etiology<br/>Drug and Narcotic Control<br/>Female<br/>Heart Ventricles--drug effects<br/>Humans<br/>Long QT Syndrome--chemically induced<br/>Male<br/>Middle Aged<br/>Risk Factors<br/>Selective Serotonin Reuptake Inhibitors--administration & dosage<br/>Torsades de Pointes--chemically induced<br/>United States<br/>United States Food and Drug Administration